CN Patent

CN106822125A — 一种利福霉素‑喹嗪酮双靶标分子的新用途

Assigned to Dunlop Medical (suzhou) Co Ltd · Expires 2017-06-13 · 9y expired

What this patent protects

本发明揭示了一种式Ⅰ所示的利福霉素‑喹嗪酮双靶标分子在抑制胃肠道产氨菌群中的应用。本发明式Ⅰ的利福霉素‑喹嗪酮双靶标分子与利福昔明的抗菌谱类似，对胃肠道常见产氨菌群具有更强的抗菌活性，同时具有耐药频率低的特性，在肝性脑病和与相关菌属(种)感染的预防与治疗方面具有应用前景。

USPTO Abstract

本发明揭示了一种式Ⅰ所示的利福霉素‑喹嗪酮双靶标分子在抑制胃肠道产氨菌群中的应用。本发明式Ⅰ的利福霉素‑喹嗪酮双靶标分子与利福昔明的抗菌谱类似，对胃肠道常见产氨菌群具有更强的抗菌活性，同时具有耐药频率低的特性，在肝性脑病和与相关菌属(种)感染的预防与治疗方面具有应用前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN106822125A
Jurisdiction
CN
Classification
—
Expires
2017-06-13
Drug substance claim
No
Drug product claim
No
Assignee
Dunlop Medical (suzhou) Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.